{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:07:17Z","timestamp":1788880037435,"version":"build-2803163510"},"reference-count":107,"publisher":"American Veterinary Medical Association (AVMA)","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized human oncology and are emerging as a promising strategy in veterinary cancer care. These agents unleash antitumor immunity by targeting inhibitory pathways that suppress T-cell function, enabling durable responses in select patients. In dogs, the immune checkpoint programmed cell death protein 1 (PD-1) axis is a primary focus due to conserved structural and functional homology with the PD-1 axis in humans, documented PD-1\/programmed death-ligand 1 (PD-L1) signaling in the canine tumor microenvironment, and its role in reversing tumor-induced immune exhaustion. Several caninized anti-PD-1 and anti-PD-L1 antibodies have demonstrated favorable safety profiles and notable antitumor activity in spontaneously occurring canine cancers, particularly melanoma and mast cell tumors. Gilvetmab, currently the only veterinary ICI available commercially, has conditional licensure in the United States for these indications. This caninized anti-PD-1 monoclonal antibody has demonstrated target engagement, acceptable tolerability, and clinical efficacy in a subset of treated dogs. Although reported adverse events are generally manageable, further work is needed to better characterize immune-mediated toxicities. Furthermore, response patterns may differ from those of cytotoxic therapies, including potential pseudoprogression, necessitating careful selection of response assessment methods. Key challenges remain in optimizing patient selection, refining biomarker development, establishing effective combination strategies, and defining the efficacy of immune checkpoint blockade across diverse tumor histologic subtypes (histotypes). Continued study of gilvetmab and related agents should advance the clinical application of immunotherapy in veterinary oncology and inform the next generation of comparative cancer care.<\/jats:p>","DOI":"10.2460\/javma.26.06.0517","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:20:06Z","timestamp":1788877206000},"page":"1-11","source":"Crossref","is-referenced-by-count":0,"title":["Gilvetmab advances immune checkpoint inhibitor immunotherapy for canine cancer"],"prefix":"10.2460","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0717-8157","authenticated-orcid":true,"given":"Esther","family":"Chon","sequence":"first","affiliation":[{"name":"Merck Animal Health, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Greene","sequence":"additional","affiliation":[{"name":"Merck Animal Health, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9054-7773","authenticated-orcid":true,"given":"Matthew L.","family":"Stock","sequence":"additional","affiliation":[{"name":"Merck Animal Health, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"8","key":"B1","series-title":"Cell","first-page":"2254","article-title":"Hallmarks of cancer-then and now, and beyond","volume":"189","author":"Hanahan D","year":"2026","unstructured":"Hanahan D. Hallmarks of cancer-then and now, and beyond. Cell. 2026;189(8):2254\u20132277. doi:10.1016\/j.cell.2025.12.049"},{"issue":"26","key":"B2","series-title":"N Engl J Med","first-page":"2443","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian SL","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u20132454. doi:10.1056\/NEJMoa1200690"},{"issue":"12","key":"B3","series-title":"Biomedicines","first-page":"2746","article-title":"Coley\u2019s toxin to first approved therapeutic vaccine-a brief historical account in the progression of immunobiology-based cancer treatment","volume":"12","author":"Devaraja K","year":"2024","unstructured":"Devaraja K, Singh M, Sharan K, Aggarwal S. Coley\u2019s toxin to first approved therapeutic vaccine-a brief historical account in the progression of immunobiology-based cancer treatment. Biomedicines. 2024;12(12):2746. doi:10.3390\/biomedicines12122746"},{"issue":"4","key":"B4","series-title":"Oncotarget","first-page":"7175","article-title":"The concept of immune surveillance against tumors. The first theories","volume":"8","author":"Ribatti D","year":"2017","unstructured":"Ribatti D. The concept of immune surveillance against tumors. The first theories. Oncotarget. 2017;8(4):7175\u20137180. doi:10.18632\/oncotarget.12739"},{"issue":"2","key":"B5","series-title":"J Urol","first-page":"180","article-title":"Intracavitary Bacillus Calmette-Gu\u00e9rin in the treatment of superficial bladder tumors","volume":"116","author":"Morales A","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Gu\u00e9rin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180\u2013183. doi:10.1016\/S0022-5347(17)58737-6"},{"issue":"8","key":"B6","series-title":"J Clin Oncol","first-page":"1328","article-title":"A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients","volume":"6","author":"Feinberg B","year":"1988","unstructured":"Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol. 1988;6(8):1328\u20131334. doi:10.1200\/JCO.1988.6.8.1328"},{"issue":"7","key":"B7","series-title":"J Clin Oncol","first-page":"2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins MB","year":"1999","unstructured":"Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105\u20132116. doi:10.1200\/JCO.1999.17.7.2105"},{"issue":"1","key":"B8","series-title":"Mol Cancer","first-page":"136","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang M","year":"2025","unstructured":"Zhang M, Liu C, Tu J, et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer. 2025;24(1):136. doi:10.1186\/s12943-025-02305-x"},{"issue":"6230","key":"B9","series-title":"Science","first-page":"74","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce JA","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74\u201380. doi:10.1126\/science.aaa6204"},{"issue":"1","key":"B10","series-title":"Immunity","first-page":"1","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen DS","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310. doi:10.1016\/j.immuni.2013.07.012"},{"issue":"25","key":"B11","series-title":"J Clin Oncol","first-page":"2780","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka RH","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780\u20132788. doi:10.1200\/JCO.2014.58.3377"},{"issue":"5","key":"B12","series-title":"N Engl J Med","first-page":"411","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff PW","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u2013422. doi:10.1056\/NEJMoa1001294"},{"issue":"6","key":"B13","series-title":"Blood","first-page":"2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney DG","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood. 1997;90(6):2188\u20132195. doi:10.1182\/blood.V90.6.2188"},{"issue":"16","key":"B14","series-title":"N Engl J Med","first-page":"1509","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp SA","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u20131518. doi:10.1056\/NEJMoa1215134"},{"issue":"1","key":"B15","series-title":"Discov Oncol","first-page":"209","article-title":"Immune checkpoint blockade in cancer: current insights and future horizons","volume":"17","author":"Saman H","year":"2026","unstructured":"Saman H, Makni-Maalej K, El-Ella DMA, et al. Immune checkpoint blockade in cancer: current insights and future horizons. Discov Oncol. 2026;17(1):209. doi:10.1007\/s12672-025-04361-7"},{"issue":"4","key":"B16","series-title":"Nat Rev Cancer","first-page":"252","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll DM","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u2013264. doi:10.1038\/nrc3239"},{"issue":"26","key":"B17","series-title":"N Engl J Med","first-page":"2521","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u20132532. doi:10.1056\/NEJMoa1503093"},{"issue":"6349","key":"B18","series-title":"Science","first-page":"409","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le DT","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u2013413. doi:10.1126\/science.aan6733"},{"issue":"2","key":"B19","series-title":"N Engl J Med","first-page":"123","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer J","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123\u2013135. doi:10.1056\/NEJMoa1504627"},{"issue":"8","key":"B20","series-title":"N Engl J Med","first-page":"711","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi FS","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u2013723. doi:10.1056\/NEJMoa1003466"},{"issue":"17","key":"B21","series-title":"J Clin Oncol","first-page":"1889","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf D","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889\u20131894. doi:10.1200\/JCO.2014.56.2736"},{"issue":"21","key":"B22","series-title":"N Engl J Med","first-page":"2006","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow MA","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006\u20132017. doi:10.1056\/NEJMoa1414428"},{"issue":"1","key":"B23","series-title":"N Engl J Med","first-page":"24","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi HA","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334. doi:10.1056\/NEJMoa2109970"},{"issue":"7","key":"B24","series-title":"Cancer Rep (Hoboken)","first-page":"e70234","article-title":"Therapeutic indications of pembrolizumab in eight common cancers: current evidence and future directions","volume":"8","author":"Mansour R","year":"2025","unstructured":"Mansour R, Shreba A, Khaddour K, Georgeos M, Alshehabi Z. Therapeutic indications of pembrolizumab in eight common cancers: current evidence and future directions. Cancer Rep (Hoboken). 2025;8(7):e70234. doi:10.1002\/cnr2.70234"},{"key":"B25","series-title":"Front Immunol","first-page":"2935","article-title":"A role for dogs in advancing cancer immunotherapy research","author":"Dow S","year":"2019","unstructured":"Dow S. A role for dogs in advancing cancer immunotherapy research. Front Immunol. 2019;10:2935. doi:10.3389\/fimmu.2019.02935"},{"issue":"10","key":"B26","series-title":"PLoS Med","first-page":"e1000161","article-title":"The comparative oncology trials consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway","volume":"6","author":"Gordon I","year":"2009","unstructured":"Gordon I, Paoloni M, Mazcko C, Khanna C. The comparative oncology trials consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med. 2009;6(10):e1000161. doi:10.1371\/journal.pmed.1000161"},{"issue":"7","key":"B27","series-title":"PLoS One","first-page":"e0235518","article-title":"Development of canine PD-1\/PD-L1 specific monoclonal antibodies and amplification of canine T cell function","volume":"15","author":"Choi JW","year":"2020","unstructured":"Choi JW, Withers SS, Chang H, et al. Development of canine PD-1\/PD-L1 specific monoclonal antibodies and amplification of canine T cell function. PLoS One. 2020;15(7):e0235518. doi:10.1371\/journal.pone.0235518"},{"issue":"4","key":"B28","series-title":"Vet Comp Oncol","first-page":"1487","article-title":"PD-1 expression by canine t cells and functional effects of PD-1 blockade","volume":"15","author":"Coy J","year":"2017","unstructured":"Coy J, Caldwell A, Chow L, Guth A, Dow S. PD-1 expression by canine t cells and functional effects of PD-1 blockade. Vet Comp Oncol. 2017;15(4):1487\u20131502. doi:10.1111\/vco.12294"},{"issue":"6","key":"B29","series-title":"PLoS One","first-page":"e98415","article-title":"Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade","volume":"9","author":"Maekawa N","year":"2014","unstructured":"Maekawa N, Konnai S, Ikebuchi R, et al. Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade. PLoS One. 2014;9(6):e98415. doi:10.1371\/journal.pone.0098415"},{"issue":"8","key":"B30","series-title":"PLoS One","first-page":"e0157176","article-title":"Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma","volume":"11","author":"Maekawa N","year":"2016","unstructured":"Maekawa N, Konnai S, Okagawa T, et al. Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma. PLoS One. 2016;11(8):e0157176. doi:10.1371\/journal.pone.0157176"},{"key":"B31","series-title":"Front Immunol","first-page":"1570717","article-title":"Development of caninized anti-CTLA-4 antibody as salvage combination therapy for anti-PD-L1 refractory tumors in dogs","author":"Maekawa N","year":"2025","unstructured":"Maekawa N, Konnai S, Watari K, et al. Development of caninized anti-CTLA-4 antibody as salvage combination therapy for anti-PD-L1 refractory tumors in dogs. Front Immunol. 2025;16:1570717. doi:10.3389\/fimmu.2025.1570717"},{"issue":"1","key":"B32","series-title":"MAbs","first-page":"2004638","article-title":"Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors","volume":"13","author":"Mason NJ","year":"2021","unstructured":"Mason NJ, Chester N, Xiong A, et al. Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors. MAbs. 2021;13(1):2004638. doi:10.1080\/19420862.2021.2004638"},{"key":"B33","series-title":"Vet Immunol Immunopathol","first-page":"19","article-title":"Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1","author":"Nemoto Y","year":"2018","unstructured":"Nemoto Y, Shosu K, Okuda M, Noguchi S, Mizuno T. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1. Vet Immunol Immunopathol. 2018;198:19\u201325. doi:10.1016\/j.vetimm.2018.02.007"},{"issue":"3","key":"B34","series-title":"In Vivo","first-page":"195","article-title":"Programmed cell death ligand 1 expression in canine cancer","volume":"30","author":"Shosu K","year":"2016","unstructured":"Shosu K, Sakurai M, Inoue K, et al. Programmed cell death ligand 1 expression in canine cancer. In Vivo. 2016;30(3):195\u2013204."},{"issue":"3","key":"B35","series-title":"J Vet Intern Med","first-page":"aalag098","article-title":"Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor","volume":"40","author":"Chon E","year":"2026","unstructured":"Chon E, Morsey M, Katz T, et al. Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor. J Vet Intern Med 2026;40(3):aalag098. doi:10.1093\/jvimsj\/aalag098"},{"issue":"11","key":"B36","series-title":"Cancers (Basel)","first-page":"3013","article-title":"Enhanced systemic antitumour immunity by hypofractionated radiotherapy and anti-PD-L1 therapy in dogs with pulmonary metastatic oral malignant melanoma","volume":"15","author":"Deguchi T","year":"2023","unstructured":"Deguchi T, Maekawa N, Konnai S, et al. Enhanced systemic antitumour immunity by hypofractionated radiotherapy and anti-PD-L1 therapy in dogs with pulmonary metastatic oral malignant melanoma. Cancers (Basel) 2023;15(11):3013. doi:10.3390\/cancers15113013"},{"issue":"9","key":"B37","series-title":"Vet Sci","first-page":"850","article-title":"Exploratory, randomized, dose-response study of the anti-PD-L1 antibody HFC-L1\/c4G12 in dogs with pulmonary metastatic oral malignant melanoma","volume":"12","author":"Hosoya K","year":"2025","unstructured":"Hosoya K, Kim S, Kinoshita R, et al. Exploratory, randomized, dose-response study of the anti-PD-L1 antibody HFC-L1\/c4G12 in dogs with pulmonary metastatic oral malignant melanoma. Vet Sci. 2025;12(9):850. doi:10.3390\/vetsci12090850"},{"issue":"1","key":"B38","series-title":"J Immunother Cancer","first-page":"e013623","article-title":"Caninized PD-1 monoclonal antibody in oral malignant melanoma: efficacy and exploratory biomarker analysis","volume":"14","author":"Igase M","year":"2026","unstructured":"Igase M, Hagimori K, Inanaga S, et al. Caninized PD-1 monoclonal antibody in oral malignant melanoma: efficacy and exploratory biomarker analysis. J Immunother Cancer 2026;14(1):e013623. doi:10.1136\/jitc-2025-013623"},{"issue":"1","key":"B39","series-title":"J Vet Sci","first-page":"e15","article-title":"Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors","volume":"25","author":"Igase M","year":"2024","unstructured":"Igase M, Inanaga S, Nishibori S, et al. Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors. J Vet Sci. 2024;25(1):e15. doi:10.4142\/jvs.23144"},{"issue":"4","key":"B40","series-title":"Vet Comp Oncol","first-page":"901","article-title":"Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: a follow-up case report","volume":"20","author":"Igase M","year":"2022","unstructured":"Igase M, Inanaga S, Tani K, et al. Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: a follow-up case report. Vet Comp Oncol. 2022;20(4):901\u2013905. doi:10.1111\/vco.12829"},{"issue":"1","key":"B41","series-title":"Sci Rep","first-page":"18311","article-title":"A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs","volume":"10","author":"Igase M","year":"2020","unstructured":"Igase M, Nemoto Y, Itamoto K, et al. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. Sci Rep. 2020;10(1):18311. doi:10.1038\/s41598-020-75533-4"},{"issue":"10","key":"B42","series-title":"PLoS One","first-page":"e0291727","article-title":"Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours","volume":"18","author":"Maekawa N","year":"2023","unstructured":"Maekawa N, Konnai S, Hosoya K, et al. Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours. PLoS One. 2023;18(10):e0291727. doi:10.1371\/journal.pone.0291727"},{"issue":"1","key":"B43","series-title":"NPJ Precis Oncol","first-page":"10","article-title":"PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma","volume":"5","author":"Maekawa N","year":"2021","unstructured":"Maekawa N, Konnai S, Nishimura M, et al. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol. 2021;5(1):10. doi:10.1038\/s41698-021-00147-6"},{"issue":"1","key":"B44","series-title":"Sci Rep","first-page":"8951","article-title":"A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma","volume":"7","author":"Maekawa N","year":"2017","unstructured":"Maekawa N, Konnai S, Takagi S, et al. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Sci Rep. 2017;7(1):8951. doi:10.1038\/s41598-017-09444-2"},{"issue":"12","key":"B45","series-title":"J Vet Med Sci","first-page":"1419","article-title":"Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1\/c4G12 in dogs with malignant tumors: an exploratory study","volume":"87","author":"Takagi S","year":"2025","unstructured":"Takagi S, Tagawa M, Maekawa N, et al. Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1\/c4G12 in dogs with malignant tumors: an exploratory study. J Vet Med Sci. 2025;87(12):1419\u20131425. doi:10.1292\/jvms.25-0303"},{"key":"B46","series-title":"Front Vet Sci","first-page":"1144869","article-title":"Reversing stage III oral adenocarcinoma in a dog treated with anti-canine PD-1 therapeutic antibody: a case report","author":"Xu S","year":"2023","unstructured":"Xu S, Xie J, Wang S, et al. Reversing stage III oral adenocarcinoma in a dog treated with anti-canine PD-1 therapeutic antibody: a case report. Front Vet Sci. 2023;10:1144869. doi:10.3389\/fvets.2023.1144869"},{"key":"B47","series-title":"Front Immunol","first-page":"1163633","article-title":"The role of PD-1 signaling in health and immune-related diseases","author":"Chen RY","year":"2023","unstructured":"Chen RY, Zhu Y, Shen YY, et al. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023;14:1163633. doi:10.3389\/fimmu.2023.1163633"},{"issue":"3","key":"B48","series-title":"Nat Rev Immunol","first-page":"153","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe AH","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153\u2013167. doi:10.1038\/nri.2017.108"},{"key":"B49","series-title":"Immunol Rev","first-page":"219","article-title":"The PD-1 pathway in tolerance and autoimmunity","author":"Francisco LM","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219\u2013242. doi:10.1111\/j.1600-065X.2010.00923.x"},{"issue":"10","key":"B50","series-title":"Am J Transplant","first-page":"2575","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella LV","year":"2012","unstructured":"Riella LV, Paterson AM, Sharpe AH, Chandraker A. Role of the PD-1 pathway in the immune response. Am J Transplant. 2012;12(10):2575\u20132587. doi:10.1111\/j.1600-6143.2012.04224.x"},{"issue":"5","key":"B51","series-title":"Trends Immunol","first-page":"265","article-title":"PD-1: an inhibitory immunoreceptor involved in peripheral tolerance","volume":"22","author":"Nishimura H","year":"2001","unstructured":"Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001;22(5):265\u2013268. doi:10.1016\/S1471-4906(01)01888-9"},{"issue":"7","key":"B52","series-title":"J Exp Med","first-page":"1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman GJ","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u20131034. doi:10.1084\/jem.192.7.1027"},{"key":"B53","series-title":"Front Immunol","first-page":"487","article-title":"The role of PD-1 in acute and chronic infection","author":"Jubel JM","year":"2020","unstructured":"Jubel JM, Barbati ZR, Burger C, et al. The role of PD-1 in acute and chronic infection. Front Immunol. 2020;11:487. doi:10.3389\/fimmu.2020.00487"},{"issue":"1\u20132","key":"B54","series-title":"For Immunopathol Dis Therap","first-page":"7","article-title":"Reinvigorating exhausted T cells by blockade of the PD-1 pathway","volume":"6","author":"Lee J","year":"2015","unstructured":"Lee J, Ahn E, Kissick HT, Ahmed R. Reinvigorating exhausted T cells by blockade of the PD-1 pathway. For Immunopathol Dis Therap. 2015;6(1\u20132):7\u201317. doi:10.1615\/ForumImmunDisTher.2015014188"},{"issue":"2","key":"B55","series-title":"J Exp Med","first-page":"231","article-title":"A critical role for the programmed death ligand 1 in fetomaternal tolerance","volume":"202","author":"Guleria I","year":"2005","unstructured":"Guleria I, Khosroshahi A, Ansari MJ, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med. 2005;202(2):231\u2013237. doi:10.1084\/jem.20050019"},{"issue":"10","key":"B56","series-title":"Transl Oncol","first-page":"100811","article-title":"Programmed cell death-ligand 2: a neglected but important target in the immune response to cancer?","volume":"13","author":"Solinas C","year":"2020","unstructured":"Solinas C, Aiello M, Rozali E, Lambertini M, Willard-Gallo K, Migliori E. Programmed cell death-ligand 2: a neglected but important target in the immune response to cancer? Transl Oncol. 2020;13(10):100811. doi:10.1016\/j.tranon.2020.100811"},{"issue":"7","key":"B57","series-title":"Br J Cancer","first-page":"1196","article-title":"Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy","volume":"128","author":"Wang Y","year":"2023","unstructured":"Wang Y, Du J, Gao Z, et al. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer. 2023;128(7):1196\u20131207. doi:10.1038\/s41416-022-02084-y"},{"issue":"6","key":"B58","series-title":"Cell Rep","first-page":"1189","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz A","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189\u20131201. doi:10.1016\/j.celrep.2017.04.031"},{"issue":"6","key":"B59","series-title":"Nat Immunol","first-page":"492","article-title":"T cell exhaustion","volume":"12","author":"Wherry EJ","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492\u2013499. doi:10.1038\/ni.2035"},{"issue":"6","key":"B60","series-title":"Cell","first-page":"1229","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang CH","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229\u20131241. doi:10.1016\/j.cell.2015.08.016"},{"issue":"7718","key":"B61","series-title":"Nature","first-page":"382","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen G","year":"2018","unstructured":"Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382\u2013386. doi:10.1038\/s41586-018-0392-8"},{"key":"B62","series-title":"Nat Commun","first-page":"6692","article-title":"PD-1 alters t-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","author":"Patsoukis N","year":"2015","unstructured":"Patsoukis N, Bardhan K, Chatterjee P, et al. PD-1 alters t-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692. doi:10.1038\/ncomms7692"},{"issue":"6","key":"B63","series-title":"Cancer Immunol Res","first-page":"480","article-title":"Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade","volume":"5","author":"Zhou J","year":"2017","unstructured":"Zhou J, Mahoney KM, Giobbie-Hurder A, et al. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res. 2017;5(6):480\u2013492. doi:10.1158\/2326-6066.CIR-16-0329"},{"issue":"7","key":"B64","series-title":"Thorac Cancer","first-page":"1058","article-title":"Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"12","author":"Brito ABC","year":"2021","unstructured":"Brito ABC, Camandaroba MPG, de Lima VCC. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. Thorac Cancer. 2021;12(7):1058\u20131066. doi:10.1111\/1759-7714.13867"},{"key":"B65","series-title":"Expert Rev Anticancer Ther","first-page":"1","article-title":"Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis","author":"Ding J","year":"2025","unstructured":"Ding J, Liu Z, Ning J, Sun N. Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis. Expert Rev Anticancer Ther. 2025:1\u20139. doi:10.1080\/14737140.2025.2465901"},{"issue":"6","key":"B66","series-title":"JAMA Oncol","first-page":"375","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan J","year":"2020","unstructured":"Duan J, Cui L, Zhao X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 2020;6(6):375\u2013384. doi:10.1001\/jamaoncol.2019.5367"},{"issue":"7","key":"B67","series-title":"Biomedicines","first-page":"1827","article-title":"Anti-PD-1 monoclonal antibodies (mAbs) are superior to anti-PD-L1 mAbs when combined with chemotherapy in first-line treatment for metastatic non-small cell lung cancer (mNSCLC): a network meta-analysis","volume":"11","author":"Wei JQ","year":"2023","unstructured":"Wei JQ, Yuile A, Itchins M, et al. Anti-PD-1 monoclonal antibodies (mAbs) are superior to anti-PD-L1 mAbs when combined with chemotherapy in first-line treatment for metastatic non-small cell lung cancer (mNSCLC): a network meta-analysis. Biomedicines. 2023;11(7):1827. doi:10.3390\/biomedicines11071827"},{"issue":"8","key":"B68","series-title":"Med","first-page":"100669","article-title":"Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: a comprehensive reanalysis of randomized controlled trials","volume":"6","author":"Zhang C","year":"2025","unstructured":"Zhang C, Wu P, Li D, et al. Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: a comprehensive reanalysis of randomized controlled trials. Med. 2025;6(8):100669. doi:10.1016\/j.medj.2025.100669"},{"issue":"7","key":"B69","series-title":"Vet Sci","first-page":"120","article-title":"Prognostic value of PD-L1, PD-1 and CD8A in canine diffuse large B-cell lymphoma detected by RNAscope","volume":"8","author":"Aresu L","year":"2021","unstructured":"Aresu L, Marconato L, Martini V, et al. Prognostic value of PD-L1, PD-1 and CD8A in canine diffuse large B-cell lymphoma detected by RNAscope. Vet Sci. 2021;8(7):120. doi:10.3390\/vetsci8070120"},{"key":"B70","series-title":"Vet Immunol Immunopathol","first-page":"110142","article-title":"Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours","author":"Ariyarathna H","year":"2020","unstructured":"Ariyarathna H, Thomson NA, Aberdein D, et al. Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours. Vet Immunol Immunopathol. 2020;230:110142. doi:10.1016\/j.vetimm.2020.110142"},{"issue":"2","key":"B71","series-title":"Vet Comp Oncol","first-page":"141","article-title":"PD-L1, PD-1, and CTLA-4 mRNA in situ expression by canine oral melanoma cells and immune cells of the tumour microenvironment","volume":"23","author":"Foiani G","year":"2025","unstructured":"Foiani G, Melchiotti E, Capello K, et al. PD-L1, PD-1, and CTLA-4 mRNA in situ expression by canine oral melanoma cells and immune cells of the tumour microenvironment. Vet Comp Oncol. 2025;23(2):141\u2013151. doi:10.1111\/vco.13039"},{"issue":"3","key":"B72","series-title":"Vet Comp Oncol","first-page":"352","article-title":"Checkpoint molecule expression by B and T cell lymphomas in dogs","volume":"16","author":"Hartley G","year":"2018","unstructured":"Hartley G, Elmslie R, Dow S, Guth A. Checkpoint molecule expression by B and T cell lymphomas in dogs. Vet Comp Oncol. 2018;16(3):352\u2013360. doi:10.1111\/vco.12386"},{"issue":"2","key":"B73","series-title":"Vet Comp Oncol","first-page":"534","article-title":"Immune regulation of canine tumour and macrophage PD-L1 expression","volume":"15","author":"Hartley G","year":"2017","unstructured":"Hartley G, Faulhaber E, Caldwell A, et al. Immune regulation of canine tumour and macrophage PD-L1 expression. Vet Comp Oncol. 2017;15(2):534\u2013549. doi:10.1111\/vco.12197"},{"issue":"1","key":"B74","series-title":"BMC Vet Res","first-page":"681","article-title":"Tumor immune microenvironment and immune phenotypes in PD-L1-tested canine urothelial carcinoma","volume":"21","author":"Muscatello LV","year":"2025","unstructured":"Muscatello LV, D\u2019Annunzio G, Franceschini T, et al. Tumor immune microenvironment and immune phenotypes in PD-L1-tested canine urothelial carcinoma. BMC Vet Res. 2025;21(1):681. doi:10.1186\/s12917-025-05045-8"},{"issue":"3","key":"B75","series-title":"Vet Pathol","first-page":"393","article-title":"PDL1 immunohistochemistry in canine neoplasms: validation of commercial antibodies, standardization of evaluation, and scoring systems","volume":"61","author":"Muscatello LV","year":"2024","unstructured":"Muscatello LV, Gobbo F, Avallone G, et al. PDL1 immunohistochemistry in canine neoplasms: validation of commercial antibodies, standardization of evaluation, and scoring systems. Vet Pathol. 2024;61(3):393\u2013401. doi:10.1177\/03009858231209410"},{"key":"B76","series-title":"Vet Immunol Immunopathol","first-page":"110367","article-title":"Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines","author":"Pinard CJ","year":"2022","unstructured":"Pinard CJ, Hocker SE, Poon AC, et al. Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines. Vet Immunol Immunopathol. 2022;243:110367. doi:10.1016\/j.vetimm.2021.110367"},{"issue":"1","key":"B77","series-title":"Vet Comp Oncol","first-page":"109","article-title":"Immunohistochemical expression of programmed death-ligand 1 and cytotoxic T-lymphocyte antigen-4 in canine cutaneous mast cell tumours","volume":"23","author":"Ribeiro MP","year":"2025","unstructured":"Ribeiro MP, Canadas-Sousa A, Aluai-Cunha C, de F\u00e1tima Carvalho M, Santos AF. Immunohistochemical expression of programmed death-ligand 1 and cytotoxic T-lymphocyte antigen-4 in canine cutaneous mast cell tumours. Vet Comp Oncol. 2025;23(1):109\u2013115. doi:10.1111\/vco.13036"},{"issue":"7","key":"B78","series-title":"PLoS One","first-page":"e0201222","article-title":"Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma","volume":"13","author":"Tagawa M","year":"2018","unstructured":"Tagawa M, Kurashima C, Takagi S, et al. Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma. PLoS One. 2018;13(7):e0201222. doi:10.1371\/journal.pone.0201222"},{"key":"B79","series-title":"Front Immunol","first-page":"133","article-title":"Immunotherapy for dogs: running behind humans","author":"Klingemann H","year":"2018","unstructured":"Klingemann H. Immunotherapy for dogs: running behind humans. Front Immunol. 2018;9:133. doi:10.3389\/fimmu.2018.00133"},{"key":"B80","series-title":"Front Vet Sci","first-page":"1593333","article-title":"Human immuno-therapeutics for cancer treatment of dogs?","author":"Klingemann H","year":"2025","unstructured":"Klingemann H. Human immuno-therapeutics for cancer treatment of dogs? Front Vet Sci. 2025;12:1593333. doi:10.3389\/fvets.2025.1593333"},{"issue":"4","key":"B81","series-title":"Animals (Basel)","first-page":"472","article-title":"Current review of monoclonal antibody therapeutics in small animal medicine","volume":"15","author":"Wang J","year":"2025","unstructured":"Wang J, Zhou X, Elazab ST, et al. Current review of monoclonal antibody therapeutics in small animal medicine. Animals (Basel). 2025;15(4):472. doi:10.3390\/ani15040472"},{"issue":"24","key":"B82","series-title":"Cancers (Basel)","first-page":"6188","article-title":"Development of monoclonal antibodies targeting canine PD-L1 and PD-1 and their clinical relevance in canine apocrine gland anal sac adenocarcinoma","volume":"14","author":"Minoli L","year":"2022","unstructured":"Minoli L, Licenziato L, Kocikowski M, et al. Development of monoclonal antibodies targeting canine PD-L1 and PD-1 and their clinical relevance in canine apocrine gland anal sac adenocarcinoma. Cancers (Basel). 2022;14(24):6188. doi:10.3390\/cancers14246188"},{"issue":"1","key":"B83","series-title":"Vet Q","first-page":"1","article-title":"Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry in vitro","volume":"43","author":"Sirivisoot S","year":"2023","unstructured":"Sirivisoot S, Boonkrai C, Wongtangprasert T, et al. Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry in vitro. Vet Q. 2023;43(1):1\u20139. doi:10.1080\/01652176.2023.2240380"},{"issue":"5","key":"B84","series-title":"J Vet Sci","first-page":"e75","article-title":"Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors","volume":"22","author":"Song DW","year":"2021","unstructured":"Song DW, Ro WB, Park HM. Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors. J Vet Sci. 2021;22(5):e75. doi:10.4142\/jvs.2021.22.e75"},{"issue":"3","key":"B85","series-title":"Mol Ther Oncol","first-page":"201036","article-title":"Nanobody-based canine PD-L1-targeting immune checkpoint inhibitors for cancer therapy in dogs","volume":"33","author":"Di Palma Subran M","year":"2025","unstructured":"Di Palma Subran M, Wyss M, Taskoparan B, et al. Nanobody-based canine PD-L1-targeting immune checkpoint inhibitors for cancer therapy in dogs. Mol Ther Oncol. 2025;33(3):201036. doi:10.1016\/j.omton.2025.201036"},{"issue":"3","key":"B86","series-title":"Vet Comp Oncol","first-page":"176","article-title":"Response evaluation criteria for solid tumours in dogs (v1.0): a veterinary cooperative oncology group (VCOG) consensus document","volume":"13","author":"Nguyen SM","year":"2015","unstructured":"Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. 2015;13(3):176\u2013183. doi:10.1111\/vco.12032"},{"issue":"1","key":"B87","series-title":"Radiology","first-page":"87","article-title":"Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis","volume":"297","author":"Park HJ","year":"2020","unstructured":"Park HJ, Kim KW, Pyo J, et al. Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis. Radiology. 2020;297(1):87\u201396. doi:10.1148\/radiol.2020200443"},{"issue":"3","key":"B88","series-title":"Lancet Oncol","first-page":"e143","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour L","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u2013e152. doi:10.1016\/S1470-2045(17)30074-8"},{"issue":"7","key":"B89","series-title":"Cancer Immunol Immunother","first-page":"2483","article-title":"The landscape of objective response rate of anti-PD-1\/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating","volume":"72","author":"Mao Y","year":"2023","unstructured":"Mao Y, Xie H, Lv M, et al. The landscape of objective response rate of anti-PD-1\/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating. Cancer Immunol Immunother. 2023;72(7):2483\u20132498. doi:10.1007\/s00262-023-03441-3"},{"issue":"4","key":"B90","series-title":"Vet Comp Oncol","first-page":"417","article-title":"Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","year":"2016","unstructured":"Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2016;14(4):417\u2013446. doi:10.1111\/vco.283"},{"issue":"28","key":"B91","series-title":"J Clin Oncol","first-page":"2872","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour KC","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36(28):2872\u20132878. doi:10.1200\/JCO.2018.79.0006"},{"issue":"12","key":"B92","series-title":"Oncoimmunology","first-page":"e1500108","article-title":"Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system","volume":"7","author":"Maxwell R","year":"2018","unstructured":"Maxwell R, Luksik AS, Garzon-Muvdi T, et al. Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. Oncoimmunology. 2018;7(12):e1500108. doi:10.1080\/2162402X.2018.1500108"},{"key":"B93","series-title":"Int Immunopharmacol","first-page":"108031","article-title":"Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment","author":"Wang Y","year":"2021","unstructured":"Wang Y, Yang M, Tao M, et al. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment. Int Immunopharmacol. 2021;99:108031. doi:10.1016\/j.intimp.2021.108031"},{"key":"B94","series-title":"Front Immunol","first-page":"1544949","article-title":"Prior corticosteroid treatment alters cPBMC composition and IFNgamma response to immunotherapy in canine cancer","author":"Zimmermann ABE","year":"2025","unstructured":"Zimmermann ABE, Taskoparan B, Fuchs D, et al. Prior corticosteroid treatment alters cPBMC composition and IFNgamma response to immunotherapy in canine cancer. Front Immunol. 2025;16:1544949. doi:10.3389\/fimmu.2025.1544949"},{"issue":"2","key":"B95","series-title":"Immunol Allergy Clin North Am","first-page":"285","article-title":"Hypersensitivity reactions and immune-related adverse events to immune checkpoint inhibitors: approaches, mechanisms, and models","volume":"42","author":"Park BC","year":"2022","unstructured":"Park BC, Stone CA Jr, Dewan AK, Johnson DB. Hypersensitivity reactions and immune-related adverse events to immune checkpoint inhibitors: approaches, mechanisms, and models. Immunol Allergy Clin North Am. 2022;42(2):285\u2013305. doi:10.1016\/j.iac.2021.12.006"},{"issue":"1","key":"B96","series-title":"J Immunother Cancer","first-page":"e003551","article-title":"Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition","volume":"10","author":"Henderson Berg MH","year":"2022","unstructured":"Henderson Berg MH, Del Rincon SV, Miller WH. Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition. J Immunother Cancer. 2022;10(1):e003551. doi:10.1136\/jitc-2021-003551"},{"issue":"7","key":"B97","series-title":"JAMA Oncol","first-page":"1008","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang Y","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008\u20131019. doi:10.1001\/jamaoncol.2019.0393"},{"issue":"12","key":"B98","series-title":"JAMA Oncol","first-page":"1721","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721\u20131728. doi:10.1001\/jamaoncol.2018.3923"},{"issue":"12","key":"B99","series-title":"Ann Oncol","first-page":"1217","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u20131238. doi:10.1016\/j.annonc.2022.10.001"},{"issue":"1","key":"B100","series-title":"Immunol Rev","first-page":"335","article-title":"Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: from basic science to clinical application","volume":"321","author":"Ghiringhelli F","year":"2024","unstructured":"Ghiringhelli F, Rebe C. Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: from basic science to clinical application. Immunol Rev. 2024;321(1):335\u2013349. doi:10.1111\/imr.13263"},{"issue":"8","key":"B101","series-title":"Lancet Oncol","first-page":"e352","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch C","year":"2024","unstructured":"Lynch C, Pitroda SP, Weichselbaum RR. Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 2024;25(8):e352\u2013e362. doi:10.1016\/S1470-2045(24)00075-5"},{"issue":"6477","key":"B102","series-title":"Science","first-page":"eaax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian SL","year":"2020","unstructured":"Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477):eaax0182. doi:10.1126\/science.aax0182"},{"issue":"14","key":"B103","series-title":"N Engl J Med","first-page":"1345","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok JD","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u20131356. doi:10.1056\/NEJMoa1709684"},{"key":"B104","series-title":"Front Immunol","first-page":"1162700","article-title":"A single-cell RNA sequencing atlas of circulating leukocytes from healthy and osteosarcoma affected dogs","author":"Ammons DT","year":"2023","unstructured":"Ammons DT, Harris RA, Hopkins LS, Kurihara J, Weishaar K, Dow S. A single-cell RNA sequencing atlas of circulating leukocytes from healthy and osteosarcoma affected dogs. Front Immunol. 2023;14:1162700. doi:10.3389\/fimmu.2023.1162700"},{"issue":"1","key":"B105","series-title":"Sci Rep","first-page":"9265","article-title":"Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy","volume":"12","author":"Maekawa N","year":"2022","unstructured":"Maekawa N, Konnai S, Asano Y, et al. Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy. Sci Rep. 2022;12(1):9265. doi:10.1038\/s41598-022-13484-8"},{"issue":"2","key":"B106","series-title":"Vet J","first-page":"226","article-title":"Peripheral blood lymphocyte\/monocyte ratio as a useful prognostic factor in dogs with diffuse large B-cell lymphoma receiving chemoimmunotherapy","volume":"206","author":"Marconato L","year":"2015","unstructured":"Marconato L, Martini V, Stefanello D, et al. Peripheral blood lymphocyte\/monocyte ratio as a useful prognostic factor in dogs with diffuse large B-cell lymphoma receiving chemoimmunotherapy. Vet J. 2015;206(2):226\u2013230. doi:10.1016\/j.tvjl.2015.07.009"},{"issue":"3","key":"B107","series-title":"Vet Comp Oncol","first-page":"657","article-title":"Critical questions in genomic diagnostics for veterinary oncology: what we need to know","volume":"24","author":"Sakthikumar S","year":"2026","unstructured":"Sakthikumar S, Siravegna G, White ME, et al. Critical questions in genomic diagnostics for veterinary oncology: what we need to know. Vet Comp Oncol. 2026;24(3):657\u2013664. doi:10.1111\/vco.70068"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/aop\/javma.26.06.0517\/javma.26.06.0517.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/aop\/javma.26.06.0517\/javma.26.06.0517.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:20:06Z","timestamp":1788877206000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/aop\/javma.26.06.0517\/javma.26.06.0517.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":107,"URL":"https:\/\/doi.org\/10.2460\/javma.26.06.0517","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}